Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies

NCT00129337 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT00129337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2005
Completion date
August 31, 2009
Enrollment
28 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

tumors